Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iron chelator, prostate cancer conundrum on deck for ODAC

This article was originally published in Scrip

Executive Summary

The summer is over, and with a newly reorganized and renamed office under his reign, Dr Richard Pazdur, director of the US FDA's OHOP – the Office of Hematology and Oncology Products, and not, as some might assume, a moniker for the "Orderly House of Pazdur" – is ready to get back to work, seeking to cram as much into the agency's 14 September advisory committee hearing as possible, which the cancer drug chief has tended to do at recent meetings.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014445

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel